Eli Lilly and Company – NYSE:LLY
Eli Lilly and Company stock price today
$698.5
-84.66
-10.81%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Eli Lilly and Company stock price monthly change
-17.42%
month
Eli Lilly and Company stock price quarterly change
-17.42%
quarter
Eli Lilly and Company stock price yearly change
+34.68%
year
Eli Lilly and Company key metrics
Market Cap | 740.37B |
Enterprise value | 771.22B |
P/E | 84.30 |
EV/Sales | 18.87 |
EV/EBITDA | 61.62 |
Price/Sales | 18.19 |
Price/Book | 49.55 |
PEG ratio | -1.99 |
EPS | 6.69 |
Revenue | 35.93B |
EBITDA | 15.53B |
Income | 6.13B |
Revenue Q/Q | 25.97% |
Revenue Y/Y | 29.75% |
Profit margin | 20.48% |
Oper. margin | 35.33% |
Gross margin | 81.56% |
EBIT margin | 35.33% |
EBITDA margin | 43.23% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEli Lilly and Company stock price history
Eli Lilly and Company stock forecast
Eli Lilly and Company financial statements
Average Price Target
$1,041.5
Potential upside: 49.10%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 8.31B | 1.76B | 21.21% |
|---|---|---|---|
| Sep 2023 | 9.49B | -57.4M | -0.6% |
| Dec 2023 | 9.35B | 2.18B | 23.41% |
| Mar 2024 | 8.76B | 2.24B | 25.58% |
0.66%
Yield TTM
| Payout ratio | 54.12% |
|---|
| 2019 | 1.97% |
|---|---|
| 2020 | 1.75% |
| 2021 | 1.23% |
| 2022 | 1.07% |
| 2023 | 0.77% |
| Jun 2023 | 54814000000 | 43.66B | 79.66% |
|---|---|---|---|
| Sep 2023 | 57915500000 | 46.60B | 80.48% |
| Dec 2023 | 64006300000 | 53.14B | 83.03% |
| Mar 2024 | 63943500000 | 51.04B | 79.83% |
| Jun 2023 | 631.9M | -459.1M | -1.03B |
|---|---|---|---|
| Sep 2023 | 2.18B | -3.08B | 572M |
| Dec 2023 | -311.9M | -2.92B | 3.54B |
| Mar 2024 | 1.16B | -1.17B | -311.3M |
Eli Lilly and Company alternative data
Eli Lilly and Company Social Media Accounts
What are followers?
+0.25%
month
+1.34%
quarter
| Sep 2023 | 246229 |
|---|
+5.24%
month
| May 2025 | 43656 |
|---|---|
| Jul 2025 | 46217 |
| Aug 2025 | 48637 |
Areas of Focus
| 4 Aug 2024 | 7 | 4 | 73 | 0 | 2 |
|---|---|---|---|---|---|
| 11 Aug 2024 | 7 | 5 | 76 | 0 | 2 |
| 18 Aug 2024 | 7 | 5 | 75 | 0 | 2 |
| 25 Aug 2024 | 8 | 5 | 79 | 0 | 2 |
| 1 Sep 2024 | 8 | 5 | 74 | 0 | 2 |
| 8 Sep 2024 | 7 | 5 | 76 | 0 | 2 |
| 15 Sep 2024 | 7 | 5 | 76 | 0 | 2 |
| 22 Sep 2024 | 7 | 4 | 75 | 0 | 2 |
| 29 Sep 2024 | 7 | 5 | 76 | 0 | 2 |
| 6 Oct 2024 | 7 | 5 | 73 | 0 | 2 |
| 13 Oct 2024 | 6 | 4 | 70 | 0 | 2 |
| 20 Oct 2024 | 7 | 4 | 81 | 0 | 2 |
| 27 Oct 2024 | 7 | 5 | 80 | 0 | 2 |
| 3 Nov 2024 | 6 | 3 | 77 | 0 | 2 |
| 10 Nov 2024 | 7 | 5 | 73 | 0 | 2 |
| 17 Nov 2024 | 7 | 5 | 73 | 0 | 2 |
| 24 Nov 2024 | 6 | 4 | 69 | 0 | 2 |
| 1 Dec 2024 | 5 | 3 | 62 | 0 | 1 |
| 8 Dec 2024 | 5 | 2 | 64 | 0 | 1 |
| 15 Dec 2024 | 7 | 4 | 71 | 0 | 2 |
Eli Lilly
| 21 May 2023 | 8 |
|---|---|
| 28 May 2023 | 7 |
| 4 Jun 2023 | 8 |
| 11 Jun 2023 | 11 |
| 18 Jun 2023 | 8 |
| 25 Jun 2023 | 8 |
| 2 Jul 2023 | 19 |
| 9 Jul 2023 | 20 |
| 16 Jul 2023 | 9 |
| 23 Jul 2023 | 12 |
| 30 Jul 2023 | 8 |
| 6 Aug 2023 | 24 |
| 13 Aug 2023 | 11 |
| 20 Aug 2023 | 9 |
| 27 Aug 2023 | 9 |
| 3 Sep 2023 | 9 |
| 10 Sep 2023 | 10 |
| 17 Sep 2023 | 7 |
| 24 Sep 2023 | 5 |
| 1 Oct 2023 | 7 |
Eli Lilly Products
| 26 Feb 2023 | 3 | 32 | 6 | 75 | 3 |
|---|---|---|---|---|---|
| 5 Mar 2023 | 3 | 32 | 6 | 68 | 1 |
| 12 Mar 2023 | 3 | 39 | 7 | 71 | 1 |
| 19 Mar 2023 | 3 | 36 | 6 | 67 | 2 |
| 26 Mar 2023 | 2 | 36 | 7 | 69 | 2 |
| 2 Apr 2023 | 4 | 36 | 7 | 73 | 1 |
| 9 Apr 2023 | 3 | 34 | 7 | 71 | 0 |
| 16 Apr 2023 | 5 | 33 | 6 | 73 | 1 |
| 23 Apr 2023 | 2 | 35 | 6 | 74 | 2 |
| 30 Apr 2023 | 3 | 32 | 5 | 64 | 2 |
| 7 May 2023 | 4 | 29 | 7 | 64 | 1 |
| 14 May 2023 | 2 | 36 | 8 | 66 | 0 |
| 21 May 2023 | 3 | 37 | 6 | 69 | 1 |
| 28 May 2023 | 2 | 33 | 6 | 62 | 1 |
| 4 Jun 2023 | 3 | 35 | 6 | 75 | 0 |
| 11 Jun 2023 | 3 | 33 | 8 | 69 | 0 |
| 18 Jun 2023 | 4 | 35 | 7 | 72 | 0 |
| 25 Jun 2023 | 1 | 31 | 5 | 59 | 0 |
| 2 Jul 2023 | 3 | 25 | 4 | 61 | 1 |
| 9 Jul 2023 | 3 | 36 | 7 | 68 | 1 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 694 |
|---|---|
| Oct 2023 | 639 |
| Nov 2023 | 717 |
| Dec 2023 | 665 |
| Jan 2024 | 738 |
| Feb 2024 | 833 |
| Jan 2025 | 951 |
| Feb 2025 | 1,115 |
| May 2025 | 1,205 |
| Jul 2025 | 1,085 |
| Aug 2025 | 1,004 |
| Sep 2023 | 39,000 |
|---|---|
| Oct 2023 | 39,000 |
| Nov 2023 | 39,000 |
| Dec 2023 | 39,000 |
| Jan 2024 | 39,000 |
| Feb 2024 | 39,000 |
| Mar 2024 | 43,000 |
| Apr 2024 | 43,000 |
| May 2024 | 43,000 |
| Jun 2024 | 43,000 |
| Jul 2024 | 43,000 |
Eli Lilly and Company other data
85.49%
-1.03%
of LLY is owned by hedge funds
2.24K
+11
779.43M
-8.60M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 435000 |
| Feb 2024 | 0 | 435000 |
| Mar 2024 | 0 | 750 |
| May 2024 | 0 | 250000 |
| Jul 2024 | 0 | 364810 |
| Aug 2024 | 0 | 28498 |
| Sep 2024 | 0 | 24084 |
| Nov 2024 | 0 | 900 |
| Patent |
|---|
Grant Filling date: 31 Oct 2019 Issue date: 13 Sep 2022 |
Grant Filling date: 31 Oct 2019 Issue date: 13 Sep 2022 |
Grant Utility: CD226 agonist antibodies Filling date: 19 Jul 2019 Issue date: 13 Sep 2022 |
Grant Filling date: 22 Feb 2018 Issue date: 13 Sep 2022 |
Application Filling date: 18 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 5 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 25 Aug 2020 Issue date: 8 Sep 2022 |
Application Filling date: 9 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 13 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 19 Aug 2020 Issue date: 1 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Viking Therapeutics: Still On Track
Novo Nordisk: Negative Streak Finally Ended
Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target
Eli Lilly: Don't Bet Against This Biotech Powerhouse
It's Time To Be All-In On Novo Nordisk
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
What To Do With These Seven Stocks After They Plunged
Eli Lilly: Another Not-To-Miss Dip
-
What's the price of Eli Lilly and Company stock today?
One share of Eli Lilly and Company stock can currently be purchased for approximately $698.5.
-
When is Eli Lilly and Company's next earnings date?
Unfortunately, Eli Lilly and Company's (LLY) next earnings date is currently unknown.
-
Does Eli Lilly and Company pay dividends?
Yes, Eli Lilly and Company pays dividends and its trailing 12-month yield is 0.66% with 54% payout ratio. The last Eli Lilly and Company stock dividend of $0.98 was paid on 10 Mar 2022.
-
How much money does Eli Lilly and Company make?
Eli Lilly and Company has a market capitalization of 740.37B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.56% to 34.12B US dollars.
-
What is Eli Lilly and Company's stock symbol?
Eli Lilly and Company is traded on the NYSE under the ticker symbol "LLY".
-
What is Eli Lilly and Company's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Eli Lilly and Company?
Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Eli Lilly and Company's key executives?
Eli Lilly and Company's management team includes the following people:
- Mr. David A. Ricks Chairman, Chief Executive Officer & Pres(age: 57, pay: $4,240,000)
- Dr. Daniel M. Skovronsky Senior Vice President, Chief Scientific Officer & Pres of Lilly Research Labs(age: 51, pay: $2,140,000)
- Ms. Anat Hakim J.D. Senior Vice President, Gen. Counsel & Sec.(age: 56, pay: $1,720,000)
-
How many employees does Eli Lilly and Company have?
As Jul 2024, Eli Lilly and Company employs 43,000 workers.
-
When Eli Lilly and Company went public?
Eli Lilly and Company is publicly traded company for more then 53 years since IPO on 1 Jun 1972.
-
What is Eli Lilly and Company's official website?
The official website for Eli Lilly and Company is lilly.com.
-
Where are Eli Lilly and Company's headquarters?
Eli Lilly and Company is headquartered at Lilly Corporate Center, Indianapolis, IN.
-
How can i contact Eli Lilly and Company?
Eli Lilly and Company's mailing address is Lilly Corporate Center, Indianapolis, IN and company can be reached via phone at +31 72762000.
-
What is Eli Lilly and Company stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Eli Lilly and Company in the last 12 months, the avarage price target is $1,041.5. The average price target represents a 49.10% change from the last price of $698.5.
Eli Lilly and Company company profile:
Eli Lilly and Company
lilly.comExchange:
NYSE
Full time employees:
43,000
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Lilly Corporate Center
Indianapolis, IN 46285
Indianapolis, IN 46285
CIK: 0000059478
ISIN: US5324571083
CUSIP: 532457108
